Clinical Trial: Durability of Three Monthly Loading Doses with Faricimab Injections in Patients with Treatment-naive Neovascular Age-related Macular Degeneration

U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06890026) titled 'Durability of Three Monthly Loading Doses with Faricimab Injections in Patients with Treatment-naive Neovascular Age-related Macular Degeneration' on March 16.

Brief Summary: Neovascular Age-Related Macular Degeneration (nAMD) is a one of the leading causes of irreversible vision loss among the elderly in developed countries. The implementation of anti-VEGF therapies in the last decades has significantly improved AMD management. Faricimab (Vabysmo(R)), a bispecific antibody targeting both Vascular Endothelial Growth Factor A (VEGF-A) and Angiopoietin-2 (Ang-2), offers enhanced disease control by both inhibiting angiogenesis and sta...